Apr 17 |
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
|
Apr 4 |
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
Apr 4 |
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
|
Mar 28 |
Stoke Therapeutics prices upsized equity offering of $125M
|
Mar 28 |
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
|
Mar 27 |
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
|
Mar 26 |
Stoke Therapeutics announces proposed public offering worth $75M
|
Mar 26 |
Stoke Therapeutics Announces Proposed Public Offering
|
Mar 26 |
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
|
Mar 26 |
Stoke stock rockets 73% on updated epilepsy drug data
|